Regeneron Pharmaceuticals, Inc. (REGN) Financial Statements (2024 and earlier)

Company Profile

Business Address 777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
State of Incorp. NY
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,9288,9607,7427,0227,5667,051
Cash and cash equivalents1,9373,9163,1063,4913,3953,346
Short-term investments6,9915,0434,6363,5304,1713,705
Restricted cash and investments 6     
Receivables5,1215,1195,3295,5485,1614,839
Inventory, net of allowances, customer advances and progress billings2,5082,4252,4022,4122,2191,992
Inventory2,5082,4252,4022,4122,2191,992
Other undisclosed current assets361406411446584425
Total current assets:16,92316,90915,88415,42915,53014,306
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization   620   
Property, plant and equipment    3,7043,6383,556
Long-term investments and receivables6,3276,0676,5925,9696,4167,084
Long-term investments6,3276,0676,5925,9696,4167,084
Intangible assets, net (including goodwill)953929916804  
Intangible assets, net (excluding goodwill)953929916804  
Restricted cash and investments7     
Deferred income tax assets2,1391,9251,7241,4521,3521,140
Other noncurrent assets393350336320270262
Other undisclosed noncurrent assets3,9163,8813,143   
Total noncurrent assets:13,73513,15113,33012,24911,67612,043
TOTAL ASSETS:30,65830,06029,21527,67827,20626,349
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5476002,074   
Accounts payable547600589   
Accrued liabilities   1,135   
Other undisclosed accounts payable and accrued liabilities   350   
Deferred revenue381426478547566491
Other undisclosed current liabilities2,1762,0745892,3322,4682,516
Total current liabilities:3,1043,1003,1412,8793,0343,008
Noncurrent Liabilities
Long-term debt and lease obligation2,7022,7022,7012,7012,7012,700
Long-term debt, excluding current maturities1,9821,9821,9811,9811,9811,980
Finance lease, liability720720720720720720
Liabilities, other than long-term debt833763708659783726
Deferred revenue1168670605934
Other liabilities717677638599725693
Total noncurrent liabilities:3,5353,4653,4093,3603,4843,426
Total liabilities:6,6406,5656,5516,2396,5186,434
Equity
Equity, attributable to parent, including:24,01823,49522,66421,43920,68819,915
Treasury stock, value(11,766)(11,046)(10,353)(9,914)(9,003)(8,611)
Additional paid in capital10,88910,5989,9499,5189,1208,754
Accumulated other comprehensive loss(198)(182)(239)(275)(224)(170)
Retained earnings25,09324,12523,30722,11020,79419,942
Other undisclosed equity, attributable to parent000000
Total equity:24,01823,49522,66421,43920,68819,915
TOTAL LIABILITIES AND EQUITY:30,65830,06029,21527,67827,20626,349

Income Statement (P&L) ($ in millions)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues3,1583,1623,4142,9362,8572,965
Cost of revenue(404)(513)(564)(272)(477)(413)
Cost of goods and services sold   (157)(35)(19) 
Gross profit:2,7542,6492,8502,6642,3812,552
Operating expenses(1,737)(1,702)(1,704)(1,440)(1,271)(1,294)
Other operating income, net117461720
Other undisclosed operating loss(1)(1)(7)(46)(17)(20)
Operating income:1,0179471,1471,2241,1101,259
Nonoperating income (expense)66(89)178286(147)(197)
Other nonoperating income (expense)85(71)195301(134)(184)
Interest and debt expense(19)(18)(17)(15)(13)(14)
Income from continuing operations before equity method investments, income taxes:1,0648401,3071,4959501,048
Other undisclosed income from continuing operations before income taxes191817151314
Income from continuing operations before income taxes:1,0838581,3251,5109631,061
Income tax expense(115)(40)(128)(194)(111)(88)
Income from continuing operations:9688181,1971,316852974
Income before gain (loss) on sale of properties:1,316852974
Net income available to common stockholders, diluted:9688181,1971,316852974

Comprehensive Income ($ in millions)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income:9688181,1971,316852974
Other comprehensive income (loss)(16)57 (51)(54)(144)
Other undisclosed comprehensive loss   (213)   
Comprehensive income:9528759851,264798830
Other undisclosed comprehensive income, net of tax, attributable to parent   249   
Comprehensive income, net of tax, attributable to parent:9528751,2331,264798830

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: